March 28, 2019 5:55pm

The upside was strong while down weak …

With the IBB (+0.61%), NASDAQ (+0.34%) and the A/D <advance/decline> line (30/14) of 45 covered companies reversed Wednesday’s decline (8/35)

Pre-open indications: 5 Hits and 1 MISS

 

How many times is your portfolio profiting from solid  intel or advice from advisors?

Duty, honor and shareholders should be a mantra – it’s mine!

My “quantamental” blend of styles; must become the “tool” for investors and traders to portfolio enrichment.

 

Markets and indexes:

  • The Dow closed up +91.87 points or +0.36% to 25,717.46
  • The S&P closed up +10.07 points or +0.36% to 2,815.44
  • The NASDAQ was up +25.79 points or +0.34% to 7,669.17

 

Henry’omics:

Sector equities rose on Thursday as the oversold screamed “BUY” while trade talks between China and the U.S. restarted, but fears that the economy may be slowing.

In economic news, the U.S. economy grew by 2.2% in Q4/18, according to the government’s final read was released.

I listen and write about quarterly and fiscal year (FY) results and continued to be amazed at the temerity i.e. reckless confidence that comes across as offensive of some management teams in a review of their progress over years of lack of execution and progress!

 

Cell and gene therapy companies worst-performers were:  VSTM (-$0.24), BMRN (-$0.13), QURE (-$0.12), ADVM (-$0.10) and AGTC (-$0.07) after …

  • Wednesday’s: BLUE (-$5.26), SAGE (-$4.89), IONS (-$3.15), RGNX (-$2.27) and GBT (-$1.97).
  • Tuesday’s downside: QURE (-$2.07), RENE.L (-$2.00), BLFS (-$0.87), RGNX (-$0.39) and VCEL (-$0.35);
  • After Monday’s: RENE.L (-$2.00), QURE (-$1.4), CRSP (-$1.40), BLFS (-$0.75) and BOLD (-$0.68)

 

Sector equities posting gains were: RENE.L (+$15.50), BLUE (+$5.47), ALNY (+$4.26), IONS (+$2.72) and GBT (+$1.53) after …

  • Wednesday’s: RENE.L (+$3.50), FIXX (+$0.19), CLBS (+$0.07), BCLI (+$0.07) and PSTI (+$0.017)
  • Tuesday’s: BLUE (+$6.59), SAGE (+$4.01), ALNY (+$2.97), RARE (+$2.74) and GBT (+$1.55);
  • After Monday’s: SAGE (+$2.12), GBT (+$1.38), VYGR (+$1.17), RARE (+$1.08) and AXGN (+$1.01)

 

Pre-open post, “the sector’s musical chairs has one less chair; the oversold are pushing and shoving for the remaining seats.”

 

The advance/decline line scenario of 45 covered companies:  

  • The open was positive with the A/DL to 29/12, 3 flats and 1 acquired (AST);
  • The mid-day was positive with an A/DL of 32/11 and 1 flat and 1 acquired;
  • The close was positive with an A/DL of 30/14 and 0 flat and 1 acquired;

 

Pre-open indications:  5 HIT and 1 MISS

  • BioLife Solutions (BLFS) closed up +$0.45 – hit;
  • Biostage (BSTG) closed down -$0.06 – hit;
  • uniQure NV (QURE) closed down again -$0.12 – miss;
  • CRISPER Therapeutics (CRSP) closed up +$0.72 – hit;
  • Editas medicine (EDIT) closed up +$0.68 – hit;
  • Intellia Therapeutics (NTLA) closed up +$0.33 – hit;

 

Tonight’s percentage (%) indicators: 

  • Range of the 30 upside was +0.17% (VCEL) to +20.67% (RENE.L) while the 14 downside ranged from -0.05% (OSIR) to -7.57% (VSTM).

Volume stat: 

  • 2 out of the 30 upside had higher (than the 3 month average) volume
  • 6 out of the 14 downside experienced greater volume (than the 3 month average)

0 flat with 1 acquired: 1 (AST)

 

The iShares NASDAQ Biotechnology (IBB) indicator:

  • Thursday was up +0.61%;
  • Wednesday was down -1.39%;
  • Tuesday was up +1.86%;
  • Monday was up +0.14%;
  • Friday was down -3.39%;
  • Last Thursday was down -1.07%;

 

March sessions:

Thursday closed POSITIVE with 14 decliners, 30 advancers, 0 flat and 1 acquired;

Wednesday closed NEGATIVE with 35 decliners, 8 advancers, 1 flat and 1 acquired;

Tuesday closed POSITIVE with 17 decliners, 26 advancers, 2 flats and 1 acquired;

Monday (3/25) closed POSITIVE with 21 decliners, 23 advancers, 0 flats and 1 acquired;

Friday closed NEGATIVE with 40 decliners, 2 advancers, 2 flats and 1 acquired;

Thursday closed POSITIVE with 12 decliners, 31 advancers, 1 flat and 1 acquired;

Wednesday closed NEGATIVE with 25 decliners, 18 advancers, 1 flat and 1 acquired;

Tuesday closed NEGATIVE with 22 decliners, 19 advancers, 3 flats and 1 acquired;

Monday (3/18) closed POSITIVE with 17 decliners, 27 advancers and 1 acquired;

Friday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Thursday closed NEGATIVE with 30 decliners, 13 advancers and 2 flats;

Wednesday closed POSITIVE with 12 decliners, 30 advancers and 3 flats;

Tuesday closed POSITIVE with 13 decliners, 30 advancers and 2 flats;

Monday (3/11) closed POSITIVE with 7 decliners, 37 advancers and 1 flat;

Friday closed POSITIVE with 20 decliners, 22 advancers and 3 flats;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flats;

Wednesday closed NEGATIVE with 39 decliners, 5 advancers and 1 flat;

Tuesday (3/4) closed POSITIVE with 17 decliners, 23 advancers and 5 flats;

Monday (3/1) closed NEGATIVE with 24 decliners, 18 advancers and 3 flats;

Friday (3/1) closed POSITIVE with 11 decliners, 32 advancers and 2 flats;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.